Dialysis-related carnitine disorder and levocarnitine pharmacology

American Journal of Kidney Diseases

Volumn 41, Issue 4 SUPPL. 4, 2003, Pages

  Evans, Allan ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Acetyl L carnitine; Carnitine; Chronic renal failure (CRF); Dialysis; End stage renal disease (ESRD); Kidney failure; L carnitine; Pharmacology; Uremia

Indexed keywords

ACYLCARNITINE; CARNITINE; ERYTHROPOIETIN;

AMINO ACID METABOLISM; ANEMIA; CARDIOMYOPATHY; CARNITINE DEFICIENCY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; FATTY ACID OXIDATION; HEMODIALYSIS; HOMEOSTASIS; HUMAN; HYPOTENSION; KIDNEY FAILURE; KIDNEY TUBULE ABSORPTION; MUSCLE WEAKNESS; REVIEW; SIDE EFFECT; STRUCTURE ANALYSIS;

EID: 0037379698     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(03)00113-6     Document Type: Review

References (54)

1. Bremer J: Carnitine - Metabolism and functions. Physiol Rev 63:1420-1480, 1983
2. Rebouche CJ, Paulson DJ: Carnitine metabolism and function in humans. Ann Rev Nutr 6:41-66, 1986
3. Rebouche CJ, Seim H: Carnitine metabolism and its regulation in microorganisms and mammals. Annu Rev Nutr 18:39-61, 1998
4. Pons R, De Vivo D: Primary and secondary carnitine deficiency syndromes. J Child Neurol 10:2S8-2S24, 1995 (suppl 2)
5. Harper P, Wadstrom C, Cederblad G: Carnitine measurements in liver, muscle tissue, and blood in normal subjects. Clin Chem 39:592-599, 1993
6. Lombard KA, Olson A, Nelson SE, Rebouche CJ: Carnitine status of lactoovovegetarians and strict vegetarian adults and children. Am J Clin Nutr 50:301-306, 1989
7. Cooper M, Forte C, Jones D: Carnitine and acetylcarnitine in red blood cells. Biochim Biophys Acta 959:100-105, 1988
8. Brass EP: Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients. Clin Ther 17:176-185, 1995
9. Rebouche CJ: Quantitative estimation of absorption and degradation of a carnitine supplement by human adults. Metabolism 40:1305-1310, 1991
10. Rebouche CJ, Chenard CA: Metabolic fate of dietary carnitine in human adults: Identification and quantification of urinary and fecal metabolites. J Nutr 121:539-546, 1991
11. Harper P, Elwin C, Cederblad G: Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. Eur J Clin Pharmacol 35:69-75, 1988
12. Sahajwalla CG, Helton ED, Purich EE, et al: Multipledose pharmacokinetics and bioequivalence of L-carnitine 330-mg tablet versus 1-g chewable tablet versus enteral solution in healthy adult male volunteers. J Pharm Sci 84:627-633, 1995
13. Segre G, Bianchi E, Corsi M, D'Iddio S, Ghirardi O, Maccari F: Plasma and urine pharmacokinetics of free and of short-chain carnitine after administration of carnitine in man. Arzneimittelforschung 38:1830-1834, 1988
14. Vaz FM, Wanders RJA: Carnitine biosynthesis in mammals. Biochem J 361:417-429, 2002
15. Marzo A, Arrigoni Martelli E, Mancinelli A, et al: Protein binding of L-carnitine family components. Eur J Drug Metab Pharmacokinet 364-368, 1991 (special no. 3)
16. Pace S, Longo A, Toon S, Rolan P, Evans AM: Pharmacokinetics of propionyl-L-carnitine in humans: Evidence for saturable tubular reabsorption. Br J Clin Pharmacol 50:441-448, 2000
17. Engel AG, Rebouche CJ, Wilson DM, Glasgow AM, Romshe CA, Cruse RP: Primary systemic carnitine deficiency. II. Renal handling of carnitine. Neurology 31:819-825, 1981
18. Rebouche CJ, Lombard KA, Chenard CA: Renal adaptation to dietary carnitine in humans. Am J Clin Nutr 58:660-665, 1993
19. Tamai I, Ohashi R, Nezu J, et al: Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 273: 20378-20382, 1998
20. Wang Y, Ye J, Ganpathy V, Longo N: Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency. Proc Natl Acad Sci U S A 96:2356-2360, 1999
21. Brass EP: Carnitine transport, in Ferrari R, Dimauro S, Sherwood G (eds): Carnitine and Its Role in Medicine From Function to Therapy New York, NY, Academic, 1992, pp 21-36
22. Evans AM, Faul R, Fornasini G, et al: Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis. Clin Pharmacol Ther 68:238-249, 2000
23. Rebouche CJ, Engel AG: Kinetic compartmental analysis of carnitine metabolism in the human carnitine deficiency syndromes. J Clin Invest 73:857-867, 1984
24. Bartel LL, Hussey JL, Shrago E: Perturbation of serum carnitine levels in human adults by chronic renal disease and dialysis therapy. Am J Clin Nutr 34:1314-1320, 1981
25. Wanner C, Forstner-Wanner S, Rossle C, Furst P, Schollmeyer P, Horl WH: Carnitine metabolism in patients with chronic renal failure: Effect of L-carnitine supplementation. Kidney Int Suppl 22:S132-S135, 1987
26. Debska-Slizien A, Kawecka A, Wojnarowski K, et al: Correlation between plasma carnitine, muscle carnitine and glycogen levels in maintenance hemodialysis patients. Int J Artif Organs 23:90-96, 2000
27. Sakurauchi Y, Matsumoto Y, Shinzato T, et al: Effects of L-carnitine supplementation on muscular symptoms in hemodialyzed patients. Am J Kidney Dis 32:258-264, 1998
28. Bohmer T, Bergrem H, Eiklid K: Carnitine deficiency induced during intermittent haemodialysis for renal failure. Lancet 1:126-128, 1978
29. Leschke M, Rumpf KW, Eisenhauer T, et al: Quantitative assessment of carnitine loss during hemodialysis and hemofiltration. Kidney Int Suppl 16:S143-S146, 1983
30. Wanner C, Horl WH: Carnitine abnormalities in patients with renal insufficiency: Pathophysiological and therapeutical aspects. Nephron 50:89-102, 1988
31. Moorthy A, Rosenblum M, Rajaram R, Shug AL: A comparison of plasma and muscle carnitine levels in patients on peritoneal or hemodialysis for chronic renal failure. Am J Nephrol 3:205-208, 1983
32. Evans AM, Fornasini G: Pharmacokinetics of L-carnitine. Clin Pharmacokinet 2003 (in press)
33. Bellinghieri G, Savica V, Mallamace A, et al: Correlation between increased serum and tissue L-carnitine levels and improved muscle symptoms in hemodialyzed patients. Am J Clin Nutr 38:523-531, 1983
34. Bertoli M, Battistella PA, Vergani L, et al: Carnitine deficiency induced during hemodialysis and hyperlipidemia: Effect of replacement therapy. Am J Clin Nutr 34:1496-1500, 1981
35. Hiatt WR, Koziol BJ, Shapiro JI, Brass EP: Carnitine metabolism during exercise in patients on chronic hemodialysis. Kidney Int 42:1613-1619, 1992
36. Savica V, Bellinghieri G, Di Stefano C, et al: Plasma and muscle carnitine levels in haemodialysis patients with morphological-ultrastructural examination of muscle samples. Nephron 35:232-236, 1983
37. Vacha GM, Corsi M, Giorcelli G, D'Iddio S, Maccari F: Serum and muscle L-carnitine levels in hemodialyzed patients during and after long-term L-carnitine treatment. Curr Ther Res 37:505-516, 1985
38. Siami G, Clinton ME, Mrak R, Griffis J, Stone W: Evaluation of the effect of intravenous L-carnitine therapy on function structure and fatty acid metabolism of skeletal muscle in patients receiving chronic hemodialysis. Nephron 57:306-313, 1991
39. Rizza V, Lorefice R, Rizza N, Calabrese V: Pharmacokinetics of L-carnitine in human subjects, in Ferrari R, Dimauro S, Sherwood G (eds): Carnitine and Its Role in Medicine From Function to Therapy New York, NY, Academic, 1992, pp 63-77
40. Gloggler A, Bulla M, Furst P: Kinetics of intravenously administered carnitine in haemodialysed children. J Pharm Biomed Anal 3:411-414, 1990
41. Sahajwalla CG, Helton ED, Purich EE, Hoppel CL, Cabana BE: Comparison of L-carnitine pharmacokinetics with and without baseline correction following administration of single 20-mg/kg intravenous dose. J Pharm Sci 84:634-639, 1995
42. Uematsu T, Itaya T, Nishimoto M, et al: Pharmacokinetics and safety of L-carnitine infused IV in healthy subjects. Eur J Clin Pharmacol 34:213-216, 1988
43. Golper TA, Wolfson M, Ahmad S, et al: Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects. Kidney Int 38:904911, 1990
44. Ahmad S, Robertson H, Golper TA, et al: Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int 38:912-918, 1990
45. Fagher B, Cederblad G, Eriksson M, et al: L-Carnitine and haemodialysis: Double blind study on muscle function and metabolism and peripheral nerve function. Scand J Clin Lab Invest 45:169-178, 1985
46. Spagnoli LG, Palmieri G, Mauriello A, et al: Morphometric evidence of the trophic effect of L-carnitine on human skeletal muscle. Nephron 55:16-23, 1990
47. Giovenali P, Fenocchio D, Montanari G, et al: Selective trophic effect of L-carnitine in type I and IIa skeletal muscle fibres. Kidney Int 46:1616-1619, 1994
48. Gudjonsson H, Li B, Shug A, et al: Studies of carnitine metabolism in relation to intestinal absorption. Am J Physiol 248:G313-G319, 1985
49. Simenhoff ML: Metabolism and toxicity of aliphatic amines. Kidney Int Suppl 3: S314-S317, 1975
50. Simenhoff ML, Burke JF, Saukkonen JJ, Ordinario AT, Doty R: Biochemical profile of uremic breath. N Engl J Med 297:132-135, 1977
51. Simenhoff ML, Ginn HE, Teschan PE: Toxicity of aliphatic amines in uremia. Trans Am Soc Artif Intern Organs 23:560-565, 1977
52. DeLisa F, Bieber LL, Kerner J, Menabo R, Barbato R, Siliprani N: Methods for carnitine assay, in Ferrari R, Dimauro S, Sherwood G (eds): Carnitine and Its Role in Medicine From Function to Therapy New York, NY, Academic, 1992, pp 37-61
53. Longo A, Bruno G, Curti S, Mancinelli A, Miotto G: Determination of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine in human plasma by high-performance liquid chromatography after pre-column derivitization with 1-aminoanthracene. J Chromatogr B Biomed Appl 686:129-139, 1996
54. Panzetta G, Bonadonna G, Giovene P, De Grandis D: Carnitine kinetics during dialysis. Nephron 41:230-234, 1985